Samsung Biologics Acquires PolyPeptide Group in $1.8 Billion Deal
Samsung Biologics has agreed to acquire Switzerland's PolyPeptide Group for $1.8 billion, marking the largest biopharmaceutical M&A deal in South Korea’s history. The acquisition aims to expand Samsung's pipeline into peptide therapeutics and strengthen its position in the growing weight-loss drug market.
Tickers: $PPG
Topics: Biopharmaceuticals GLP-1 Peptide Therapeutics Weight Loss Drugs